Zinc Lozenges and Their Effect on Postoperative Sore Throat Syndrome
NCT ID: NCT02405832
Last Updated: 2018-08-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
87 participants
INTERVENTIONAL
2015-03-10
2015-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
When patients undergo surgery with general anesthesia, they require ventilation of their lungs with the help of a flexible tube (called an endotracheal tube) that is placed through the mouth, passing the vocal cords, and into the windpipe (trachea). This tube helps oxygenate the patient, delivers anesthetic gas to the lungs, and keeps the airways open to prevent asphyxiation. The procedure is invasive and uncomfortable, and one of the most common consequences is a sore and inflamed throat after the tube is taken out. This is termed postoperative sore throat (POST). Though the intensity and severity of sore throat varies from person to person, the reported incidence is as high as 90% of patients undergoing general anesthesia.
Zinc therapy has been shown in multiple studies to reduce the severity and duration of cold symptoms, and also to up-regulate the immune system. Recent studies have shown that zinc can act as an anti-inflammatory agent and can maintain the integrity of skin and mucosal membranes (which cover the inside of the mouth and throat). The aim of this study is to evaluate the effects of giving zinc lozenges before tube placement on postoperative sore throat.
After written informed consent is received in pre-op, a sealed and coded envelope with either the zinc lozenge or the placebo lozenge will be given to the patient to be administered orally, with the instruction to dissolve the lozenge by sucking on it 30 minutes prior to surgery. Upon completion of surgery and emergence from general anesthesia, the patient will be extubated and transferred to the post-anesthesia care unit (PACU). Once in the PACU, the patient will be assessed regarding the incidence and severity of POST by the study investigator using a standardized scale. The severity of POST will be graded on a 4-point scale ranging from 0 to 3; 0 being no sore throat, 1 being mild discomfort (complains only upon questioning), 2 being moderate sore throat (complains on his/her own), and 3 being severe sore throat (change in voice, hoarseness, and throat pain). This evaluation will be performed at 30 minutes, 2 hours, 4 hours, and 24 hours post-surgery, with the assessment at 4 hours being the primary outcome of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-operative Sore Throat and Gum Chewing
NCT04859101
Evaluation of the Efficacy of Preoperative Ketamine Nebulization on Postoperative Sore Throat Due to Tracheal Intubation for Adult Patients Under General Anesthesia, A Prospective Randomized Controlled Study
NCT05975346
Effect of Clove Oil and Menthol Lozenges on Post-extubation Sore Throat
NCT06811051
Post Operative Sore Throat and Dexamethasone
NCT01052038
Preoperative Aspirin and Benzydamine Hydrochloride Gargles on Severity and Duration of Post-Operative Sore Throat
NCT05343429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Postoperative sore throat (POST) syndrome is a very common complication of endotracheal intubation Prior to earlier studies larger endotracheal tubes were utilized for providing general anesthesia. The incidence of POST at that time was 48%, with smaller tubes the incidence decreased to 22%. It is now standard of care to utilize endotracheal tubes based on size and gender of the patient. In subsequent studies to further reduce the incidence of POST, the rate of sore throat in the control groups have been between 17-90%. The cause of POST is related to direct local tissue trauma leading to inflammation of the pharyngeal mucosa and possibly the drying effect of non-humidified gases across the mucous membranes. Although there have been multiple treatments recommended for POST, none of them have been exactly effective, and the symptoms usually ameliorate within 72 hr without treatment. Even though this is the case, it is still recommended to take preventive measures for POST. The presence of POST after surgery is a patient satisfaction issue and has also been associated with a longer stay in in the post anesthesia recovery unit(Higgins et al). Both pharmacologic and non-pharmacologic measures have been recommended in past studies. Nonpharmacological methods for attenuating POST have included using smaller-sized endotracheal tubes, lubricating the endotracheal tube with water-soluble jelly, careful airway instrumentation, and minimizing cuff pressure. Pharmacologic measures have included gargles with lidocaine, aspirin, or ketamine preoperatively, inhalation of beclomethasone or fluticasone propionate, and recently the use of licorice gargle or magnesium lozenges 30 min preoperatively (Ruetzler, Borazan H).
Zinc has been utilized for many years as a topical agent to promote epithelial health and recovery after injury. Several studies have evaluated the effect of zinc on wound healing and epithelial tissue health. These studies have shown that supplementation with zinc sulfate causes rapid recovery of leg and gastric ulcers (Worthington et al). It seems zinc not only increases re-epithelialization, but it also decreases bacterial activity and causes rapid wound healing (Arbabi-kalati et al). Zinc has also been shown to be an immunomodulatory agent that monitors and modifies the immune system and T-lymphocytes. Decreases in zinc serum levels lead to lymphopenia and declines in cellular and humoral immunity. The effect of oral zinc sulfate has also been utilized for treatment of oral wounds by oral surgeons; moreover, research has shown zinc supplementation assists with the recovery of mucosal wounds and treatment of tongue ulcers (Worthington et al). A recent study by Arbabi-kalati, showed that high dose oral zinc sulfate (220 mg TID) decreased the intensity of mucositis, xerostomia, and pain in individuals undergoing chemotherapy or radiotherapy treatments. The mechanism by which zinc improves tissue health was investigated by Sharir et al. and in a model of epithelial injury showed that topical zinc directly activates receptors that promote epithelial repair.
Keeping the above studies in mind, the investigators built this study using the protocols devised by Borazan H, in which they evaluated the efficacy of magnesium lozenges on POST. There are currently no known studies that look at the efficacy of zinc in the prevention of POST. The investigators will use custom compounded lozenges from a local pharmacy with 40 mg of elemental zinc (equivalent to 174 mg of zinc sulfate) per lozenge, which is the tolerable upper intake level for zinc in adults as defined by the US department of Food and Nutrition Board.
The possible knowledge gained from this study for POST syndrome can be extended to people undergoing surgeries requiring endotracheal intubation in the future.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zinc - active arm
Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
Zinc
Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
Placebo
Placebo lozenge, with sweetener and citrus flavor, administered orally
Placebo
Placebo lozenge, with sweetener and citrus flavor, administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zinc
Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
Placebo
Placebo lozenge, with sweetener and citrus flavor, administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologists physical status classification system I and II (healthy patient or patient with mild systemic disease)
* Patient coming for elective surgery (except head and neck) requiring general anesthesia
* Patients staying for at least 24 hours postoperatively
* Patients provide informed consent
* Patients presenting for surgery \>1 hour in length and \<6 hours.
Exclusion Criteria
* Chronic smokers
* Patients with Mallampati airway grade of more than 2
* Patients requiring more than one attempt for intubation or traumatic intubations
* Patients requiring laryngeal mask Airway (LMA) placement
* Patients allergic to zinc
* Patients requiring quinolones or tetracycline antibiotics pre- or intraoperatively
* Patients undergoing head and neck surgeries
* Pregnancy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Vermont
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lydia Grondin
Associate Professor of Anesthesiology and Attending Anesthesiologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lydia Grondin, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Vermont
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Vermont Medical Center
Burlington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Arbabi-kalati F, Arbabi-kalati F, Deghatipour M, Ansari Moghadam A. Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: a double-blind randomized clinical trial. Arch Iran Med. 2012 Jul;15(7):413-7.
Borazan H, Kececioglu A, Okesli S, Otelcioglu S. Oral magnesium lozenge reduces postoperative sore throat: a randomized, prospective, placebo-controlled study. Anesthesiology. 2012 Sep;117(3):512-8. doi: 10.1097/ALN.0b013e3182639d5f.
Higgins PP, Chung F, Mezei G. Postoperative sore throat after ambulatory surgery. Br J Anaesth. 2002 Apr;88(4):582-4. doi: 10.1093/bja/88.4.582.
Ruetzler K, Fleck M, Nabecker S, Pinter K, Landskron G, Lassnigg A, You J, Sessler DI. A randomized, double-blind comparison of licorice versus sugar-water gargle for prevention of postoperative sore throat and postextubation coughing. Anesth Analg. 2013 Sep;117(3):614-621. doi: 10.1213/ANE.0b013e318299a650. Epub 2013 Aug 6.
Sharir H, Zinger A, Nevo A, Sekler I, Hershfinkel M. Zinc released from injured cells is acting via the Zn2+-sensing receptor, ZnR, to trigger signaling leading to epithelial repair. J Biol Chem. 2010 Aug 20;285(34):26097-106. doi: 10.1074/jbc.M110.107490. Epub 2010 Jun 3.
Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A, McCabe MG, Meyer S, Khalid T. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD000978. doi: 10.1002/14651858.CD000978.pub3.
Farhang B, Grondin L. The Effect of Zinc Lozenge on Postoperative Sore Throat: A Prospective Randomized, Double-Blinded, Placebo-Controlled Study. Anesth Analg. 2018 Jan;126(1):78-83. doi: 10.1213/ANE.0000000000002494.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHRMS 14-206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.